SECOND AMENDED AND RESTATED LICENSE AND SUPPLY AGREEMENT

This Second Amended and Restated License and Supply Agreement (the "Agreement") made and entered into as of this 14th day of May, 2010, effective as of May 19, 2010 (the “Second A&R Agreement Date”), by and between Columbia Laboratories (Bermuda) Limited, a Bermuda corporation having its principal place of business at Canon’s Court, 00 Xxxxxxxx Xxxxxx, XX Xxx XX 0000, Xxxxxxxx XX 12, Bermuda ("Licensor"), and Ares Trading S.A., a Swiss company with its principal place of business at x/x Xxxx Xxxxxxxxxxxx , 0000 Xxxxxxxx, Xxxxxxxxxxx ("Licensee").

WITNESSETH:

WHEREAS, Licensor and Licensee entered into a License and Supply Agreement dated as of May 20, 1999, as such agreement was amended and restated as of June 4, 2002, and further amended by Amendment No. 1 thereto, dated December 21, 2006;

WHEREAS, this Agreement is the second amended and restated version of the License and Supply Agreement;

WHEREAS, Licensor is the owner or exclusive licensee of, and has the right to transfer or grant licenses with respect to, certain Technology, Patents and the Trademarks (as hereinafter defined);

WHEREAS, Licensor wishes to grant to Licensee an exclusive license (subject only to Licensor's retained use and manufacturing rights) to the Technology and Patents for use and sale of the Product (as hereinafter defined) in the Territory (as hereinafter defined), and Licensee wishes to receive such a license, on the terms and subject to the conditions set forth herein; and

WHEREAS, Licensor wishes to assign the Trademarks to Licensee, and Licensee wishes to accept such assignment, on the terms and subject to the conditions set forth herein, and Licensor wishes to retain for its own use the Licensor Trademark.

NOW, THEREFORE, for and in consideration of the mutual promises and covenants herein contained, the parties hereto agree as follows.

1. Definitions. As used in this Agreement, the following terms (except as otherwise expressly provided or unless the context otherwise requires) shall have the respective meanings set forth below (it being understood that the terms defined in this Agreement shall include the singular number in the plural, and the plural number in the singular):

(a) "Affiliate" shall mean any corporation or other business entity that either directly or indirectly controls a party to this Agreement, is controlled by such party, or is under common control of such party. As used herein, the term "control" means possession of the power to direct or cause the direction of the management and policies of a corporation or other entity whether through the ownership of voting securities, by contract or otherwise.

(b) "Base Price" shall mean Direct Cost plus 20%. On a country-by-country basis, Licensor shall notify Licensee of the Base Price if the Base Price becomes relevant in calculating the Purchase Price.

(c) "Confidential Information" shall mean all information and/or technical data which is disclosed by one party hereto to the other party hereto pursuant to this Agreement which the disclosing party treats as confidential and identifies as such, other than (i) information known to the receiving party or its Affiliates prior to the disclosure of such information to such party, provided said prior knowledge is supportable by documentary evidence, (ii) information which at the time of the disclosure is, or thereafter becomes, generally known to the public, provided that such public knowledge does not result from any act or disclosure by the receiving party or one of its Affiliates in violation of the terms of this Agreement, (iii) information which can be shown to be independently discovered, after the date hereof, by a party, or one of its Affiliates, without the aid, application or use of the disclosed information, or (iv) information obtained by the receiving party from a third party which is determined to be in lawful possession of such information, provided such third party is not in violation of any contractual or legal obligation to the disclosing party or one of its Affiliates with respect to such information. Confidential information of Licensor shall be deemed to include Dispensing Data disclosed by Licensor or its Affiliates to Licensee or its Affiliates, regardless of whether such Dispensing Data is identified as confidential. Confidential Information of Licensee shall be deemed to include Dispensing Data disclosed by Licensee or its Affiliates to Licensor or its Affiliates regardless of whether such Dispensing Data is identified as confidential.

(d) "Direct Cost" shall mean the following direct costs of manufacturing the Product: raw material/ingredient costs, packaging costs, direct labor and direct overhead.

(e) "Failure to Supply" shall mean Licensor fails to supply the Product in the countries of Europe taken as a whole substantially in accordance with the firm orders contained within Licensee's forecast for a continuous period of one-hundred and twenty (120) days.

(f) "FDA" shall mean the U.S. Food and Drug Administration.

(g) "Field" shall mean the vaginal delivery of progesterone or progestational agents alone or in combination or co-administered with other active substances directed toward use in hormone replacement therapy as well as in the indications of secondary amenorrhea, in vitro fertilization, and prevention of endometrial hyperplasia and other indications where progesterone or progestational agents are commonly used except in a locally acting - non-systemic - contraceptive where progesterone or a progestational agent may be useful.

(h) "Finished Package Form" shall mean applicators wrapped in aluminum foil with required leaflet printed in two colors and inserted into an appropriate box with customary trade dress printed in up to four colors. The boxes will be placed into appropriate outer cartons which will be printed in one color with required labeling and UPC codes.

(i) "Forecast" shall mean the official Licensee forecast as required by paragraphs 4 (i) and 4 (j).

(j) "GMP" shall mean current good manufacturing practice regulations promulgated by the FDA and other regulatory agencies.

(k) "Intellectual Property Rights" shall mean trade secrets, trademarks, tradenames, logos, trade dress, graphics, designs, patents, copyrights or other proprietary rights.

(l) “Licensee Domain Names” shall mean domain names and or social media addresses related to the Product that are not a Licensor Domain Name. The Licensee Domain Names as of the Second A&R Agreement Date are listed on Schedule F.

(m) “Licensee Trademarks” shall mean the trademarks set forth on Schedule G.

(n) “Licensor Domain Name” shall mean domain names and or social media addresses related to the Product as set forth in Schedule E.

(o) “Licensor Trademark” shall mean the trademark CRINONE in the United States subject to U.S. Patent & Trademark Registration No. 2,086,161.

(p) "Low Viscosity Product" shall mean any batch of Product that, as of the initial release testing by Licensor of such Product or its contract manufacturer, has a viscosity that meets the viscosity specification in the applicable regulatory filing, but falls below 53,500 cps.

(q) "Marketing License Agreement" shall mean the Marketing License Agreement dated as of June 4, 2002, by and between Licensor and Licensee, which was terminated pursuant to the terms of the agreement entered into between the Parties on December 21, 2006.

(r) "NDA" shall mean a New Drug Application as defined by the FDA.

(s) "Net Sales" shall mean the aggregate equivalent of gross revenue received by Licensee, its Affiliates or sublicensees (for the sake of clarity, the definition of Net Sales hereunder shall not include any sales of Product by the Licensor) from or on account of the sale of the Product to non affiliated third parties on which payments are due under this Agreement, less (i) reasonable credits or allowances, if any, actually granted on account of cash or trade discounts, recalls, rebates, rejection or return of the Product previously sold, (ii) excises, sales taxes, value added taxes, consumption taxes, duties or other taxes imposed upon and paid with respect to such sales (excluding income or franchise taxes of any kind) and (iii) separately itemized insurance and transportation costs incurred in shipping the Product to such third parties. No deduction shall be made for any item of cost incurred by Licensee or its Affiliates in preparing, manufacturing, shipping or selling the Product except as permitted pursuant to clauses (i), (ii) or (iii) of the foregoing sentence. Net Sales shall not include any transfer between Licensee and any of its Affiliates or sublicensees for resale. No transfer of the Product for test or development purposes or as free samples shall be considered a sale hereunder for accounting and payment purposes.

(t) "Non-Fertility Specialist Market" shall have the meaning set forth in the Marketing License Agreement.

(u) "Patents" shall mean the patents and/or patent applications filed in the Territory owned by the Licensor or its Affiliates or with respect to which Licensor or its Affiliates may now or hereafter have the right to grant licenses in the Territory, the claims of which may be infringed, absent a license, by the manufacture, use or sale of the Product within the Territory, including, without limitation, the patents and applications set forth in Schedule A hereto and any and all patents issued pursuant thereto, as well as any patents to be applied for or issued to Licensor or its Affiliates in the future during the term of this Agreement, which future patents and patent applications shall be added to Schedule A by written notice of Licensor to Licensee within thirty (30) days of such application and/or issuance.

(v) "Product" shall mean progesterone/COL-1620 vaginal gel.

(w) "Product A" shall mean progesterone/COL-1620 vaginal gel containing progesterone in a concentration of four percent (4%).

(x) "Product B" shall mean progesterone/COL-1620 vaginal gel containing progesterone in a concentration of eight percent (8%).

(y) "Purchase Price" shall have the meaning set forth in Section 5 of this Agreement.

(z) "Promote" and "Promotional" shall mean, with respect to the Product, any activities undertaken by or on behalf of a party to encourage sales or use of the Product, including, without limitation, sales detail calls, product sampling, journal advertising, direct mail programs, direct-to-consumer advertising, convention exhibits and all other forms of marketing, advertising or promotion.

(aa) "Technology" shall mean all pharmacological, toxicological, preclinical, clinical, technical or other information, data and analysis and know-how relating to the registration, manufacture, packaging, use, marketing and sale of the Product (including, without limitation, all works copyrighted by Licensor) and all proprietary rights relating thereto owned by Licensor or its Affiliates or to which Licensor or its Affiliates has rights so as to be able to license, whether prior to or after the Second A&R Agreement Date, and relating or pertaining to the Product.

(bb) "Territory" shall mean all countries and territories of the world except for the United States.

(cc) "Trademarks" shall mean the trademark " CRINONE " or the trademark "PERLENCE" for use on cosmetic and pharmaceutical products used primarily for progesterone supplementation as set forth in Schedule B, but shall exclude the Licensor Trademark.

(dd) "Unit" shall mean a single applicator.

(ee) "United States" shall mean the several United States, the District of Columbia and Puerto Rico.

(ff) “US Agreement” shall mean the agreement relating to rights in the United States entered into between the Parties on December 21, 2006.

(gg) "Valid Claim" shall mean a claim which is contained in an unexpired, issued Patent which has not been held invalid or unenforceable by a decision of a court or patent office of competent jurisdiction, unappealable or unappealed within the time allowed for appeal, and which has not been admitted to be invalid by the owner through reissue or disclaimer.

(hh) “Ongoing Clinical Trials” shall mean clinical trials sponsored by Licensor and listed in attached Schedule C

(ii) ‘”New Clinical Trials” shall mean any new clinical trials relating to the Product which are initiated by Licensor or Licensee after the Second A&R Agreement Date.

2. Grant of License.

(a) Licensor grants to Licensee, and Licensee accepts from Licensor, on the terms and conditions stated herein, an exclusive (even as to Licensor and Licensor's Affiliates) right and license, with the right to sublicense, under the Patents and Technology to market, use and sell the Product in the Territory; provided, however, that Licensee will only sublicense Product containing progesterone in a concentration of eight percent (8%) after prior consultation with Licensor. Licensor grants to Licensee, and Licensee accepts from Licensor, on terms and conditions stated herein, a nonexclusive right and license with the right to sublicense its Affiliates under the Patents and Technology to make and/or have made the Product anywhere in the world, but only for use or sale in the Territory.

(b) [INTENTIONALLY OMITTED].

(c) Licensor's retained rights in the Territory in connection with the Product shall include only those rights under the Patents and Technology to make, have made and use the Product as necessary for Licensor to fulfill its commitments now or in the future with respect to this Agreement and with respect to its licensees who market the Product outside the Territory, to otherwise operate its business (it being understood that Licensor, its Affiliates and other licensees shall not sell, use or market the Product within the Territory), and to make, have made, use, market and sell the Product, itself or through its Affiliates or licensees, outside the Territory.

(d) Licensor shall not, and shall cause its Affiliates and licensees not to use the Trademarks and Licensee Domain Names outside the Territory. For the avoidance of doubt, Licensor is free to use the Licensor Trademark and Licensor Domain Names outside the Territory, and to use the Licensor Trademark in the Territory solely to manufacture, have manufactured, package, label, and export the Products for sale outside the Territory in accordance with the terms and conditions of this Agreement.

(e) Licensee may, at any time, request from Licensor, and Licensor agrees to grant directly to any party in any country of the Territory exclusive license rights consistent with those granted to Licensee herein. Accordingly, upon receipt of Licensee's request, Licensor shall enter into and sign a separate direct license agreement or agreements with the companies designated by Licensee in the request. All direct agreements shall be prepared by Licensee. In the absence or upon the expiration of laws and regulations to the contrary, the terms and conditions thereof shall not be less favorable by Licensor than those contained in this Agreement and shall be similar to the terms and conditions contained in this Agreement. Such agreements must be approved by Licensor, which approval shall not be unreasonably withheld. In those countries in which the validity of such a direct license agreement requires prior governmental approval or registration, such direct license agreement shall not be binding or have any force or effect until the required governmental approval or registration has been granted. Incidental out-of-pocket costs incurred by Licensor in the renegotiation of this Agreement, the execution of direct license agreements and matters pertaining thereto shall be for the account of Licensee, when prior approved by Licensee.

(f) In the event that any local government would request or local regulations would require that the regulatory approval for the Product be held in the name of Licensee or should it reasonably appear that ownership of the registration for the Product by Licensee would facilitate regulatory approval, then Licensor, upon the request of Licensee, shall transfer to Licensee ownership of the regulatory approval for the Product for such country or countries.

3. Trademarks.

(a) As of the Second A&R Agreement Date, Licensor presently assigns to Licensee, at Licensor’s cost, all rights to, and interest in, the Trademarks listed on Schedule B and related goodwill pursuant to the process described on Schedule D. Licensor shall reimburse Licensee for Licensee’s reasonable out-of-pocket expenses in securing the assignment of the Trademarks. All trademark licenses granted by Licensor to Licensee prior to the Second A&R Agreement Date shall terminate as of the Second A&R Agreement Date.

(b) The Licensor undertakes to not use in the Territory, for any products it produces or produced by other third parties upon its instructions or under its control, certain brands or designs that include letters, word(s), logo or symbol with any colours, which are identical or confusingly similar to the Trademarks now being assigned to the Licensee.

(c) Licensor represents and warrants to the Licensee that the rights of the Trademarks which are hereby assigned have not been encumbered with, including but not limited to, claims of infringement of third-party intellectual property rights or bound by any agreements of any nature whatsoever that limit the right of the Licensor to dispose of the Trademarks.

(d) Commencing on the Second A&R Agreement Date and continuing until all supply obligations of Licensor under the Agreement have terminated, Licensee grants to Licensor, and Licensor accepts from Licensee, on the terms and conditions stated herein, an non-exclusive right and license, with the right to sublicense, to use the Trademarks to manufacture, have manufactured, package, label, import and export the Products in accordance with the terms and conditions of this Agreement.

(e) The parties acknowledge that the Licensee has sole and exclusive ownership of the Licensee Trademarks and the Licensee Domain Names and, as of the Second A&R Agreement Date, the Trademarks.

4. Supply.

(a) During the term of the Agreement, Licensor shall supply, unless otherwise agreed, Licensee, its Affiliates and sublicensees with the Product on an exclusive basis in the Territory. All such Product shall be delivered in Finished Package Form. Also, during the term of the Agreement, Licensor shall not develop, license, manufacture nor sell to another party in the Territory any product in the Field. Licensor is not restricted from developing, licensing, manufacturing or selling other hormones or drugs. Licensor represents that as of the Second A&R Agreement Date, it has not entered into any arrangement which would contravene the intentions of this paragraph. For the avoidance of doubt, nothing in this paragraph shall be interpreted to restrict Licensor’s right to manufacture Product in the Territory for sale outside the Territory.

(b) Although Licensor is responsible for production and quality control, Licensee has the right of inspection to ensure Licensor meets all appropriate standards set by the FDA or other appropriate regulatory authorities.

(c) Licensor shall be obliged to maintain the registration of the manufacturing facilities with the appropriate regulatory authorities and to allow inspection of such facilities by regulatory authorities insofar as necessary or advisable in order to facilitate the supply to Licensee, its Affiliates or sublicensees of the Product, and promptly to notify Licensee of any inspection of its own or its contract supplier's manufacturing facilities by the regulatory authorities and promptly to provide Licensee with copies of any correspondence received from the regulatory authorities setting forth the results of any such inspection insofar as the Product is concerned. Furthermore, as may be required for regulatory purposes, Licensor grants Licensee the right to refer to, and shall cause its contract supplier to grant to Licensee access to, contract supplier's master file relating to the Product and undertakes to notify Licensee and provide Licensee with specific details of any changes to said master file or other filings by the contract supplier with the regulatory authorities relative to the Product. Licensor shall consult with Licensee before it or its contract supplier makes any material change in any manufacturing process for the Product. Licensor shall be kept duly informed without any delay by copy letter of any correspondence between Licensee and the contract supplier, in the event that any such communication should occur.

(d) Licensor shall notify Licensee or designees of Licensee acceptable to Licensor of any and all manufacturing, filling, quality control, testing and release activities involving the Product, at least ten (10) days prior to any such activities. Following such notice and upon five (5) days prior notice given by Licensee to Licensor in writing, Licensor shall permit, and shall cause its contract manufacturers to permit, representatives of Licensee or designees of Licensee acceptable to Licensor and/or its contract manufacturers (i) to observe any manufacturing, filling, quality control, testing and release activities involving the Product and facilities used by or in connection with such activities, and (ii) to perform an audit of each contract manufacturer with respect to the compliance of such contract manufacturer with GMP, provided that such representatives or designees of Licensee shall conduct such observations and audits in a manner which shall cause the least possible interruption to Licensor's and the contract manufacturers' operations under the particular circumstances. Notwithstanding the foregoing, GMP audits conducted pursuant to subsection (ii) shall be performed no more often than annually, except that additional GMP audits may be conducted by Licensee upon a specific, reasonable basis related to GMP compliance and provided that the scope of any such additional audit shall be limited to addressing the specific basis for the audit. Such observations and audits shall take place in a timely manner and shall be permitted to take place during any or all phases of manufacturing, filling, quality control and testing involving the Product. As part of such observations and audits, Licensor and its contract manufacturers shall grant Licensee access to information in their possession relevant to whether the Product is produced under GMP. Licensor shall promptly respond to any observations made by Licensee and shall take any corrective actions necessary so that it can continue to supply the Product in accordance with this Agreement.

(e) Personnel of Licensee or Licensee's designee shall be entitled to witness the manufacturing of test batches, scale-up batches and full-size production batches which in each case will be used as NDA support batches filed by Licensee or in regulatory authority presentations. These batches would be prepared by the intended commercial process for the Product or prepared to demonstrate the quality of the entire process (validation) or any single aspect of a critical manufacturing parameter. Licensee may witness and/or review the analytical laboratory testing of any of the above cited batches or of the methodology which will be used to support a regulatory authority presentation. Licensee may prospectively review, to the extent necessary for compliance with applicable GMP and for scheduling purposes, the protocols and actual study data and results (process, cleaning, sterilization, validation) as related to such batches.

(f) Licensee shall keep all information disclosed to or obtained by Licensee under paragraphs 4 (c), (d) and (e) strictly confidential and not disclose the same to any other person, except to the extent reasonably necessary or appropriate under applicable regulations for Licensee to register the Product with the regulatory authorities or otherwise comply with applicable law.

(g) The information disclosed shall be used only to check the compliance of the contract supplier with GMP or any other applicable regulation or any other purpose agreed by Licensor and the contract supplier. In no case, shall Licensee use such information to manufacture the Product, except in the case where such rights have been acquired from Licensor or transferred to Licensee.

(h) Product in Finished Packaged Form shall be delivered by Licensor so as to comply with the packaging and labeling requirements set forth by the FDA or other appropriate regulatory agencies.

(i) Licensee will supply Licensor with a sales Forecast between the time of submission of a registration file in any country of the Territory and the approval of such file by the appropriate regulatory authority in such country, so that Licensor can plan production. If Licensee or one of its Affiliates or sublicensees does not market the Product in a country within six (6) months after approval for both marketing and price, where applicable (e.g. France, Spain and Italy), Licensee will pay to Licensor twenty percent (20%) of the first year Forecast for the Product in such country for each year of delay in marketing the Product in such country. It is additionally provided that such payment will be reduced in the event Licensee or one of its Affiliates or sublicensees introduces the Product in such country within the twelve (12) month period from the date of regulatory approval therein (including price approval) to the extent of thirty percent (30%) of Net Sales for such country during said twelve (12) month period.

(j) Licensee will give Licensor, before the fifteenth (15th) day of every month, a non-binding Forecast of Licensee's, its Affiliates' and sublicensees' requirements of Product for each country in which the Product is marketed for the following eighteen (18) month period. Before the 15th day of every month, Licensee will place a firm order for Licensee’s, its Affiliates’ and sublicensees’ requirements for the one (1) month period beginning three and a half months later, and the Product described in the order will be delivered to Licensee, its Affiliates and sublicensees one hundred and twenty (120) days from the date of the order The firm orders placed by Licensee for the one month’s supply of Product shall represent in aggregate a quantity of at least one (1) batch of Product. Licensor is obliged to supply the amount of Product requested in the firm order except to the extent that such amount is more than fifteen percent (15%) higher than the amount that had been forecasted for that period in the last Forecast received by Licensor. With respect to any amount ordered in excess of the fifteen percent (15%) limit, Licensor is obligated to use commercially reasonable efforts to supply the requested amount to Licensee, its Affiliates and sublicensees.

(k) Licensor shall use reasonable commercial efforts to notify Licensee within thirty (30) days after the Second A&R Agreement Date and thereafter thirty (30) days prior to the end of each calendar year, of factory vacation schedules for the coming year, and if Licensee receives notice of such vacation schedules, they will be incorporated into Licensee's Forecasts.

(l) Licensor bears the expense and responsibility for transportation and insurance for the Product to the Licensee's choice of airport or seaport (FOB port) nearest to the manufacturing site where the Product is manufactured; thereafter, transportation, insurance and duties for the Product are the responsibility of Licensee. Each shipment of the Product shall be accompanied by a Certificate of Analysis for each lot within each shipment signed by authorized quality control/quality assurance personnel of Licensor or its contract manufacturer.

(m) Licensor shall comply with the following:

Licensor shall manufacture the Product for Licensee using three (3) or fewer shearing cycles and shall certify to Licensee on the Certificate of Analysis that the Product was manufactured using three (3) or fewer shearing cycles. Licensor shall implement and comply with the provisions of the Continuous Improvement Plan provided to Licensee and dated October 31, 2002, and shall cause each of its contract manufacturers to (i) implement and comply with such Continuous Improvement Plan, (ii) implement and comply with any plans for addressing observations or recommendations regarding the Product or the production of the Product set forth in any letter provided by such subcontractor to Licensor, and (iii) otherwise manufacture, fill, and perform quality assurance on the Product in full compliance with GMP.

Licensor shall manufacture the bulk Product in 1000 kg batches.

All Product manufactured and supplied hereunder shall meet the quality control specifications and the specifications in the applicable regulatory filing through the expiration date stated on that Product package. The Product shall be manufactured in accordance with a validated manufacturing process and the results shall be in accordance with the validated range for each parameter. Such Product when delivered to Licensee, its Affiliates and sublicensees shall also not be adulterated or misbranded within the meaning of the U.S. Food, Drug and Cosmetic Act, as amended. In accordance with GMPs and other applicable laws and regulations, Licensor or its contract manufacturer will test each shipment of the Product to be supplied to Licensee, its Affiliates and sublicensees pursuant to this Agreement before delivery of such shipment to Licensee, its Affiliates and sublicensees to ensure that the Product meets these standards.

Licensor’s stability testing program for the Product shall, at all times, include the requirement that at least one batch of product be placed on stability testing each year in accordance with the GMPs.

Licensor shall supply to Licensee all of Licensee's requirements of the Product in accordance with Section 4(j) before supplying its own requirements or that of any licensee of Licensor.

(n) Licensor shall, within forty-five (45) days following each of the first four (4) three-month periods immediately following the date of the initial release testing of each batch of Low Viscosity Product, measure and report to Licensee in writing the viscosity of each such batch of Low Viscosity Product until such time as each such Low Viscosity Product batch is shown by any such measurement to have a viscosity that equals or exceeds 53,500 cps. Licensee, its Affiliates or sublicensees may not return under this paragraph any delivered Low Viscosity Product that is shown by any such measurements to have a viscosity that equals or exceeds 53,500 cps, provided such Low Viscosity Product meets all other specifications and requirements under this Agreement. Licensee, its Affiliates and sublicensees shall have the right to (i) reject any delivered Product that does not meet quality control specifications and the specifications in the applicable regulatory filings, (ii) return to Licensor, at Licensor's expense and in accordance with Licensor's shipping instructions, any delivered Low Viscosity Product that in each of the four measurements has a viscosity below 53,500 cps, and (iii) return to Licensor, at Licensor's expense and in accordance with Licensor's shipping instructions, any delivered Low Viscosity Product if Licensee is already in possession of one batch of Low Viscosity Product that Licensee has yet to accept or return under this Section 4(n). Licensee must notify Licensor in writing of any such rejection or return within thirty (30) days (except as to latent defects) after Licensee's right to reject or return has accrued, and Licensor shall replace all batches rejected or returned by Licensee with Product that has a viscosity that equals or exceeds 53,500 cps and that meets all other specifications and requirements under this Agreement within one-hundred and twenty (120) days following rejection or return of the batch by Licensee. The expense of return, manufacture of replacement Product and shipment of replacement Product are Licensor's.

(o) Deleted

(p) In the event Licensor is unable, due to reasons beyond its control, to provide Licensee, its Affiliates and sublicensees the amount of Product set forth in any firm order, Licensor shall be obligated to provide such amount of Product to Licensee, its Affiliates and sublicensees through third parties with which Licensor contracts, and Licensor shall be responsible for any additional costs, including without limitation additional costs of manufacturing the Product, caused thereby, provided that the provisions of this sentence shall not apply to the extent that the amount of Product set forth in such firm order exceeds the Forecast by more than fifteen percent (15%).

(q) In countries (e.g. in some countries in South America or in India) where the Purchase Price of thirty percent (30%) of Net Sales for Finished Package Form of the Product is below the Base Price, Licensor will provide Licensee finished Product in tubes with reusable applicators or other appropriate presentation, at a negotiated second base price. In countries where import duties make it impractical to import Product in Finished Package Form (e.g. Argentina), Licensor will grant Licensee the right to manufacture the Product locally if requested by Licensee for such country and will be paid a royalty on Net Sales for such country, provided such royalty can be legally expatriated from any such country, equal to the difference between thirty percent (30%) of Net Sales in such country and Licensee's cost of manufacturing the Product for such country.

This royalty shall be payable for such country until the expiration of any Valid Claims in such country or until a third-party vaginally-administered progesterone product approved in such country subsequent to May 21, 1995 captures fifteen percent (15%) or more of the sales of the Product in such country. Subsequent to either event taking place in any such country, the royalty payable to Licensor on Net Sales in such country shall be reduced to seven percent (7%) in consideration of rights to the Trademarks and Technology until May 21, 2015 and thereafter the royalty payable on Net Sales in such country shall be two percent (2%) in consideration of rights to the Technology until May 21, 2020. Thereafter Licensee shall have an irrevocable fully paid up license to the Product under the Technology (subject to the condition set forth in Section 13 hereto).

(r) If after the Initial Term as defined in Section 13, the parties cannot agree upon mutually acceptable terms for supply, Licensee has the option of converting this Agreement into a license agreement and Licensee will be free to manufacture, or have manufactured, the Product, provided that Licensee pays to Licensor on a quarterly basis a royalty for the license of the Technology of fifteen percent (15%) of Net Sales.

The royalty pursuant to this paragraph (r) shall remain at fifteen (15%) of Net Sales for any country until the expiration of any Valid Claims in such country or until a third-party vaginally-administered progesterone product approved in such country subsequent to May 21, 1995 captures fifteen percent (15%) or more of the sales of the Product in such country. Subsequent to either event taking place in any country of the Territory, the royalty payable to Licensor on Net Sales in such country shall be reduced to seven percent (7%) in consideration of rights to the Trademarks and Technology until May 21, 2015, and thereafter the royalty payable on Net Sales in such country shall be two percent (2%) in consideration of right to the Technology until May 21, 2020.

(s) Each Party shall be responsible for receiving and responding to complaints and requests for information from patients and others regarding the Product sold by it and each Party shall provide reasonable assistance to the other Party in responding to such complaints and requests for information and shall be responsible for investigating and resolving any complaints. Within thirty (30) days following the end of each calendar month during the term of the Agreement, each Party shall provide the other Party with a written report detailing complaints regarding the Product received during such month, provided that each Party shall notify the other Party of serious adverse events within two (2) days following notice to either Party of such serious adverse event. During the term of this Agreement, each Party shall make available to the other Party information about the Product as may be necessary to carry out the provisions and purposes of this Agreement and the U.S. Agreement, including without limitation general medical information relating to the Product’s storage, use and safety. Each Party shall provide prompt written notice to the other Party, including relevant references, of any information which the Party giving notice believes in its reasonable judgment is material for medical information services. Material information shall include, but not be limited to, published or unpublished reports or other clinical or laboratory data received by either Party about Product safety, contraindications, treatment programs in the indications specified by the approved Product insert, stability, storage and shipping, pharmacology, and other information that either Party believes in its reasonable judgment is relevant to safe and effective Product use. The Party giving notice shall provide reasonable follow-up information and prompt written replies to verbal or written questions from the other Party pertinent to medical information services about the Product. On a periodic basis as agreed by both Parties, but no less than annually, each Party shall provide the other Party a written summary of information about the Product, which in the reasonable judgment of the Party providing the information, is material for the medial services information of the other Party.

(t) In the event any regulatory authority having jurisdiction shall so request or order, or if either party has reason to believe that any corrective action should be taken with respect to the Product supplied hereunder, including without limitation any Product recall, customer notice, restriction, change, or market action, then such party shall immediately inform the other in writing. If the party owning the relevant registration file for such Product, after consultation with the other party, deems it necessary to effect a Product corrective action then such party shall effect such corrective action in accordance with procedures agreed upon by the parties.

If the Product defect causing the corrective action shall be found to result solely from the manufacture and supply of the Product hereunder, then Licensor shall either supply a quantity of the Product without charge sufficient to enable Licensee and/or its Affiliates or sublicensees to replace all Product subject to the corrective action, or render a credit to Licensee, its Affiliates or sublicensees for such Product, at Licensee's option. Such replacement Product shall be delivered at Licensor's expense within thirty (30) days of the date on which the corrective action was effected, as Licensee may direct. In such event Licensor also agrees to reimburse Licensee, its Affiliates or sublicensees for other costs and expenses incurred with respect to such corrective action. If the Product defect causing the corrective action shall be found to result solely from one of the Party’s, its Affiliates’ or sublicensees’ marketing, use or sale of the Product, then the costs and expenses of such corrective action shall be paid by such Party. If the Product defect causing the corrective action shall be found to result from a joint act or omission of the parties, then the parties shall negotiate in good faith an appropriate allocation of the costs and expenses of the corrective action. The Licensor shall be responsible for the costs of any corrective action (i) outside of the Territory and (b) within the Territory, if found to result solely from the manufacture and supply of the Product hereunder.

(u) At any time upon the request of either party, the parties agree to cooperate and negotiate in good faith to prepare and execute a technical agreement consistent with the provisions of this Agreement and other provisions necessary for compliance with applicable laws, rules and regulations of European countries.

5. Price and Payment Terms.

(a) The Purchase Price to be paid by the Licensee for the Product in Finished Package Form shall be the Base Price or thirty percent (30%) of Net Sales, whichever is greater, unless otherwise agreed as contemplated in paragraph 4(q).

If the Base Price were to exceed thirty percent (30%) of Net Sales, the parties shall meet to discuss how to resolve the high cost of goods. The parties hereby acknowledge that the Base Price for the Product is contemplated for six (6) Units – twelve (12) days therapy in Finished Package Form. If Licensee orders the Product in the Finished Package Form containing fewer than six (6) Units the Base Price shall be reduced. This reduction will reflect a pro rata reduction in the cost of the Product based on the number of Units specified as well as any reduction in the cost of packaging. If Licensee wishes to order the Product in Finished Package Form that contains more than six (6) Units the Base Price will be adjusted accordingly.

(b) The following quantity discounts will be applied to annual purchases of the Product by Licensee, its Affiliates, or sublicensees:

(i) Over ten (10) million Units - 3.33% - which would reduce the Purchase Price to twenty-nine percent (29%) of Net Sales or the Base Price, whichever is greater.

(ii) Over twenty (20) million Units - 6.66% - which would reduce the Purchase Price to twenty-eight percent (28%) of Net Sales or the Base Price, whichever is greater.

(iii) Over thirty (30) million Units - 10% - which would reduce the Purchase Price to twenty-seven percent (27%) of Net Sales or the Base Price, whichever is greater.

(c) At Licensee's request, Licensor will supply promotional samples of the Product in Finished Package Form at a Purchase Price equal to Licensor's Direct Cost.

(d) Licensee's invoice price for the Product purchased from Licensor shall be paid in U.S. dollars thirty (30) days after the later of (A) receipt by Licensee of an invoice for such Product, or (B) the shipment by Licensor of the corresponding Product.

(i) Licensor's invoice price to Licensee and Licensee's payment to Licensor shall both be in U.S. dollars and shall be established for each Product pack for each country of the Territory at the commencement of each calendar year. For each country, the basis for the invoice price shall be the in-market local currency price from Licensee its Affiliates or sublicensees to third parties converted into U.S. dollars at the exchange rate published in the Wall Street Journal prevailing at the close of business on the first working day of the applicable calendar year.

(ii) Any necessary adjustments to such payments to reflect the actual Purchase Price for the Product shall be made forty-five (45) days after the end of each calendar quarter in the report described in paragraph 16(a), by converting local currency Net Sales into U.S. dollars based on the local currency – U.S. dollar exchange rate published in the Wall Street Journal on the last working day of the applicable calendar quarter and calculating the Purchase Price on this basis.

(iii) Underpayments or overpayments shall be calculated based on the Net Sales value of Units of the Product sold by Licensee, its Affiliates or sublicensees during the calendar quarter. Purchases by Licensee in excess of actual Unit sales by Licensee, its Affiliates or sublicensees during a given calendar quarter shall be carried over to the next calendar quarter for reconciliation. Volume discounts, as defined by paragraph 5(b), shall be taken into account in the last reconciliation of each calendar year.

(e) If a vaginally administered progesterone-containing product is approved in any country of the Territory subsequent to May 21, 1995 which product captures fifteen percent (15%) or more of the sales of the Product in such country the parties shall renegotiate price based on the economic impact upon the Licensee for any such country or countries.

6. Marketing.

(a) Licensee will be responsible for marketing and sales of the Product in the Territory. Licensee will use its diligent efforts to make the Product a commercial success by making a commitment throughout the term of the Agreement, financial and otherwise, to the Product that is no less than its commitment to those of its own brands and products in similar circumstances that it actively and aggressively promotes, in accordance with the life cycle of such products, provided, however, that Licensee shall have no such obligations with respect to the Product containing progesterone in a concentration of four percent (4%). Licensee will ensure that any sublicense it makes under the Patents and Technology to market, use and sell the Product in the Territory will contain appropriate obligations of commercial diligence.

(b) Licensee will provide quarterly sales and other marketing information useful to the Licensor in monitoring sales progress.

(c) Licensor hereby authorizes Licensee to communicate directly with regulatory authorities with respect to regulatory files for the Product owned by Licensor to the extent necessary to fulfill Licensee's responsibilities for marketing and sales of the Product in the Territory. Licensor agrees, at Licensee's request, to execute any documents or take any other actions as may be necessary or desirable to obtain authorization for Licensee so to communicate directly with such regulatory authorities.

(d) Licensee may refer to, and otherwise use, all published and unpublished studies regarding the Product in its Promotional and marketing efforts under this Agreement.

(e) Licensor acknowledges and agrees that (i) Licensee has no obligation under this Agreement or otherwise to market, promote or sell Product A; and (ii) by continuing after the Second A&R Agreement Date to market, promote and sell Product B to the Non-Fertility Specialist Market outside of the United States in a manner substantially similar to the manner Licensee has marketed, promoted and sold Product B to the Non-Fertility Specialist Market outside of the United States prior to April, 2001, Licensee shall satisfy any and all obligations it may have now or in the future under this Agreement or otherwise to market, promote or sell Product B to the Non-Fertility Specialist Market outside of the United States.

7. Clinical Trials and Registration.

(a) Licensor will be responsible for the Ongoing Clinical Trials (including costs of the Ongoing Clinical Trials).Licensor’s Ongoing Clinical Trials are attached in Schedule C.

Licensor shall promptly provide the data of the Ongoing Clinical Trials free-of-charge to Licensee and Licensee may rely upon the data from those Ongoing Clinical Trials solely for use with the Product within the Territory.

The parties shall consult from time to time regarding the use, details and timing of the Ongoing Clinical Trials to support registration filings for the Product in the Territory and in particular for Europe and key countries (e.g. Japan, China, Russia,.Brasil, India, etc).

Licensor will be responsible for registration filings for the Product outside the Territory, and shall be responsible for all relating costs and expenses.

Licensee will be responsible for registration filings for the Product within the Territory, and shall be responsible for all relating costs and expenses.

(b) Licensee shall have the right to monitor and audit the Ongoing Clinical Trials and/or other tests required by the protocols described in Schedule C for the Product.

(c) Each party will immediately notify the other of any adverse or unexpected reaction or results or any actual or potential government action relevant to clinical trials of the Product and the parties will discuss with each other measures to be undertaken to resolve any such problem.

(d) Licensor will be responsible for New Clinical Trials (including costs thereof), in new indications, if any, and relating new registration filings for the Product outside the Territory. Licensee will be responsible for New Clinical Trials (including costs thereof), in new indications, if any, and relating new registration filings for the Product within the Territory.

The parties shall consult from time to time regarding the use, scope, details and timing of the New Clinical Trials for the Product and each party shall promptly provide the other party free-of-charge with the data of the New Clinical Trials it is responsible for. Each party may rely upon the data from the other party’s New Clinical Trials solely for use with the Product within (i) the Territory, for Licensee or (ii) outside the Territory for Licensor.

8. Maintenance of Patents.

(a) Licensor shall keep Licensee currently advised of all steps taken or to be taken in the prosecution for all applications for Patents. Licensor shall have full and complete control over any reissue or reexamination or other proceedings relating to the Patents and/or Technology and of any disclaimers thereof. Licensor shall bear all costs for the maintenance and enforcement of the Patents, as well as all costs for the filing, maintenance and enforcement of all additional Patents which may be filed by the Licensor during the term hereof. If Licensor fails to carry out such obligations set forth in this Section 8(a), Licensee may carry out such obligations on Licensor's behalf at Licensor's cost and may set off such cost against amounts due to Licensor hereunder provided that such action is commercially reasonable.

(b) Licensee shall be responsible for, and bear all costs for the maintenance and enforcement of the Trademarks. If Licensee fails to carry out such obligations set forth in this Section 8(b), Licensor may carry out such obligations on Licensee's behalf at Licensor's cost and may charge such cost to Licensee, provided that such action is commercially reasonable.

(i) To the extent Licensor uses any of the Trademarks pursuant to the license granted to it by Licensee under Section 3 hereof, Licensor agrees to list the Trademarks in accordance with good customary trademark practice, and to avoid taking any action that would in any manner impair or detract from the value of the Trademarks, or the goodwill and reputation of Licensee.

(ii) To the extent Licensor uses any of the Trademarks pursuant to the license granted to it by Licensee under Section 3 hereof, Licensor agrees to use the Trademarks only in the form and manner and with appropriate legends as approved from time to time by Licensee, and not to use any other trademark or service xxxx in combination with the Trademarks without the prior written approval of Licensee, provided that such approval shall be granted unless Licensee reasonably objects on the basis that the proposed use would impair the value of the Trademarks.

9. Infringement of Patents, Technology and/or Trademarks

(a) Licensee and Licensor shall each promptly notify the other following the discovery of any alleged infringement or unauthorized use of the Patents, Technology and/or Trademarks which may come to their attention.

(b) In the event either Party learns of a third party’s patent/ technology and/or trademarks/ logo in the Territory that may infringe one of the Trademarks or Logos, or that one of the Trademarks or Logos may infringe a third party’s trademark or logo in the Territory, such Party shall promptly inform the other. The Parties shall jointly decide whether any and, if so, what action shall be taken. Costs and expenses sharing rules related to such action, and any compensation or damages awarded in such action, shall be agreed on a case by case basis between the parties before engaging into any actions.

10. Infringement of Third-Party Intellectual Property Rights.

(a) Each party hereto shall notify the other promptly of the receipt of notice of any action, suit or claim alleging infringement by the Patents, the Technology, the Trademarks or the Product of any Intellectual Property Rights of a third party.

(b) In no event shall Licensee settle any such allegation of infringement without the prior written consent of Licensor, which consent shall not be unreasonably withheld or delayed. In the event that the Licensor agrees in writing or Licensee in good faith determines that it is necessary for Licensee to make royalty or other payments to a third party in order for Licensee to make, have made, use or sell or to continue making, having made, using or selling the Product, Licensee shall be entitled to offset such amounts so paid to any third party against any amounts which may become due to Licensor under this Agreement.

11. Confidentiality.

Each party hereto shall hold all Confidential Information in confidence, use it only in connection with the performance of its obligations pursuant to this Agreement and use its diligent efforts (consistent with those which it uses to safeguard its own confidential information) to safeguard Confidential Information and to prevent the unauthorized use or disclosure of any Confidential Information. Each party hereto shall ensure that its Affiliates or employees who have access to any Confidential Information shall be made aware of and subject to these obligations. The receiving party may disclose Confidential Information to regulatory authorities for the purpose of seeking marketing approval of the Product pursuant to this agreement and may also disclose Confidential Information to individuals who have a need to know to effectuate the development and commercialization of the Product pursuant to this Agreement, provided each such individual is bound by a confidentiality obligation comparable to the obligation set forth in this Section 11. The obligations of the parties hereto under this Section 11 shall survive for five (5) years after the expiration or termination of this Agreement.

12. Representations, Warranties and Covenants and Indemnification.

(a) Licensor hereby represents, warrants and covenants the following:

(i) Licensor is a corporation duly organized, existing and in good standing under the laws of Bermuda, with full right, power and authority to enter into and perform this Agreement and to grant all of the rights, powers and authorities herein granted.

(ii) The execution, delivery and performance of this Agreement do not conflict with, violate or breach any agreement to which Licensor is a party, or Licensor's articles of incorporation or bylaws.

(iii) This Agreement has been duly executed and delivered by Licensor and is a legal, valid and binding obligation enforceable against Licensor in accordance with its terms.

(iv) Licensor shall comply with all applicable laws, consent decrees and regulations of any federal, state or other governmental authority in performing this Agreement.

(v) To the best of Licensor's knowledge and belief as of the Second A&R Agreement Date, there are no issued or pending patents, trademarks or patent or trademark applications relating to the Product that would prevent Licensee from using or selling the Product in the Territory.

(vi) To the best of Licensor's knowledge and belief as of the Second A&R Agreement Date, there are no outstanding, pending or threatened product liability or breach of warranty or other similar claims, actions, suits, demands, investigations, arbitrations, administrative or other proceedings, or orders, injunctions, judgments or decrees of any court or government agency in connection with the Product in the Territory.

(vii) To the best of Licensor's knowledge and belief as of the Second A&R Agreement Date, there are no outstanding, pending or threatened violations, notices of noncompliance, warning letters, orders, injunctions, judgments or decrees of any court or government agency, investigations, claims, actions, suits, demands, administrative or other proceedings that have resulted or might result in the revocation, suspension or modification of any regulatory approval for the Product in the Territory.

(b) Licensee hereby represents, warrants and covenants the following:

(i) Licensee is a corporation duly organized, existing and in good standing under the laws of Switzerland, with full right, power and authority to enter into and perform this Agreement.

(ii) The execution, delivery and performance of this Agreement do not conflict with, violate or breach any agreement to which Licensee is a party, or Licensee's articles of organization or bylaws.

(iii) This Agreement has been duly executed and delivered by Licensee and is a legal, valid and binding obligation enforceable against Licensee in accordance with its terms.

(iv) Licensee shall comply with all applicable laws, consent decrees and regulations of any federal, state or other governmental authority in performing this Agreement.

(i) Licensor agrees to indemnify and hold harmless Licensee, its Affiliates and sublicensees and their respective employees, agents, officers and directors from and against any claims, losses, liabilities, damages, costs and expenses (including reasonable attorneys' fees) incurred by Licensee, its Affiliates or sublicensees arising out of or in connection with any (A) breach by Licensor of any representation, warranty, covenant or obligation hereunder, (B) claim or demand of any kind for injury to a person or property arising from Licensor's or its contract manufacturer's manufacturing, packaging, or labeling of the Product; provided, that this indemnification shall not apply to the extent such claim or demand has resulted from manufacturing, packaging, or labeling conducted by or at the direction of Licensee, its Affiliates or sublicensees or from any negligent act or omission with respect to such Product by Licensee, its Affiliates, or sublicensees or their employees or agents, (C) act or omission on the part of Licensor or any of its employees, agents or contract manufacturers in the performance of this Agreement, and (D) payments, commissions or fees of any kind due to consultants or brokers retained by Licensor relating to the Product.

(ii) Licensee agrees to indemnify and hold harmless Licensor and its Affiliates and their respective employees, agents, officers and directors from and against any claims, losses, liabilities, damages, costs and expenses (including reasonable attorneys' fees) incurred by Licensor or its Affiliates arising out of or in connection with any (A) breach by Licensee of any representation, warranty, covenant or obligation hereunder, (B) claim or demand of any kind for injury to person or property arising from Licensee's, its Affiliates' or sublicensees' marketing, distribution and sale of the Product; provided, that this indemnification shall not apply to the extent such claim or demand has resulted from any negligent act or omission with respect to such Product by Licensor, its Affiliates, their employees, agent or contract manufacturers, (C) act or omission on the part of Licensee or any of its employees or agents in the performance of this Agreement, (D) third party claims alleging infringement of such third parties' Intellectual Property Rights as a result of the advertisement, promotion or marketing materials created by or at the direction of Licensee, its Affiliates or sublicensees and used in connection with the sale of the Product hereunder, and (E) payments, commissions or fees of any kind due to consultants or brokers retained by Licensee relating to the Product.

(iii) A party seeking indemnification under this paragraph 12 (c) (the "Indemnified Party") must give prompt written notice thereof to the other party (the "Indemnifying Party"). The Indemnifying Party shall have the right to defend any such claim or demand subject to the right of the Indemnified Party to participate with counsel of its choice in such defense, but the fees and expenses of such additional counsel shall be at the expense of the Indemnified Party. The Indemnified Party shall cooperate fully in all respects with the Indemnifying Party in any such compromise, settlement or defense, including, without limitation, by making available all pertinent information and personnel under its control to the Indemnifying Party. The Indemnifying Party will not compromise or settle any claim or demand (other than, after consultation with Indemnified Party, a claim or demand to be settled by the payment of money damages and/or the granting of releases) without the prior written consent of the Indemnified Party, which consent shall not be unreasonably withheld.

(iv) Each party shall maintain and keep in force for the term of this Agreement comprehensive general liability insurance including Products/Completed Operations, Contractual and Broad Form Property Damage covering its indemnification obligations hereunder with a minimum limit of Fifteen Million United States Dollars (U.S. $15,000,000) per annum combined single limit for Bodily Injury and Property Damage to be increased as appropriate consistent with prudent business practices prevailing in the pharmaceutical business. Such insurance shall be placed with a first class insurance carrier with at least a BBB rating by Standard & Poors. Promptly after the execution and delivery of this Agreement, each party shall furnish a certificate of insurance to the other party evidencing the foregoing endorsements, coverage and limits, and providing that such insurance shall not expire or be canceled or modified without at least thirty (30) days prior notice to the other party.

13. Term of License.

Except as otherwise provided for herein, and subject to the provisions of paragraph 4 (r), the Agreement shall commence on the Second A&R Agreement Date and remain in effect until May 19, 2015 (the "Initial Term"), renewable upon mutual agreement of the parties for five (5) year periods at commercial terms to be agreed upon. It is understood that if after the Initial Term or any subsequent five-year period the parties cannot agree upon mutually acceptable terms, Licensee will have the option of converting this Agreement into a license agreement and Licensee will be free to manufacture, or have manufactured, the Product. Under such circumstances, Licensor shall continue to supply the Product in Finished Package Form under the then current terms and conditions of this Agreement for as long as is necessary and will assist Licensee as necessary, including without limitation by transferring to Licensee all Technology necessary or useful to give Licensee the capability of manufacturing the Product in such a way as to communicate such Technology to Licensee promptly, effectively and economically, so that Licensee can undertake manufacture of the Product and continue the sale of the Product without interruption.

14. Termination.

(a) This Agreement may be terminated upon the mutual written agreement of the parties.

(b) Either party may terminate this Agreement forthwith by written notice to the other, if the other party commits a material breach of any part of this Agreement and such breach has not been remedied by the breaching party within sixty (60) days after written notice of such breach has been given by the other party. If the breach cannot be remedied within sixty (60) days, the breaching party may submit a plan within this sixty (60) day period, reasonably acceptable to the other party, outlining the steps that it intends taking to cure the breach and then must cure the breach in accordance with the terms of such plan or be subject to an action by the other party for termination of this Agreement pursuant to this paragraph 14 (b) for breach of such plan.

(c) This Agreement may also be terminated by written notice of one party, if the other party shall be involved in financial difficulties as evidenced:

(i) by its commencement of a voluntary case under any applicable bankruptcy code or statute, or by its authorizing, by appropriate proceedings, the commencement of such voluntary case; or

(ii) by its failing to receive dismissal of any involuntary case under any applicable bankruptcy code or statute within sixty (60) days after initiation of such action or petition; or

(iii) by its seeking relief as a debtor under any applicable law of any jurisdiction relating to the liquidation or reorganization of debtors or to the modification or alteration of the rights of creditors, or by consenting to or acquiescing in such relief; or

(iv) by the entry of an order by a court of competent jurisdiction finding it to be bankrupt or insolvent, or ordering or approving its liquidation, reorganization or any modification or alteration of the rights of its creditors or assuming custody of, or appointing a receiver or other custodian for, all or a substantial part of its property or assets; or

(v) by its making an assignment for the benefit of, or entering into a composition with its creditors, or appointing or consenting to the appointment of a receiver or other custodian for all or a substantial part of its property.

(d) Licensee may terminate this Agreement at any time during the Initial Term with one (1) year's written notice if the Product is not a commercial success, as determined by Licensee in its sole discretion, and on ninety (90) days' notice at any time during the Agreement for reasons of safety or efficacy of the Product.

(e) Licensee shall have the option of converting this Agreement into a license agreement at any time following a Failure to Supply. Upon notice of such conversion, Licensor shall assist Licensee as necessary, including, without limitation, by transferring to Licensee all Technology necessary or useful to give Licensee the capability of manufacturing the Product in such a way as to communicate such Technology to Licensee promptly, effectively and economically so that Licensee can undertake manufacture of the Product and continue the sale of the Product without interruption. Licensee shall then be free to manufacture, or have manufactured, the Product provided that Licensee pays on a quarterly basis the royalties as provided in Section 4(r).

(f) The failure by a party to exercise its rights to terminate this Agreement pursuant to this Section (14) in the event of any occurrence giving rise thereto shall not constitute a waiver of such rights in the event of any subsequent occurrence.

(g) Termination of this Agreement shall not release either party from its obligations accrued prior to the effective date of termination nor deprive either party from any rights that this Agreement provides shall survive termination. The provisions of paragraphs 4 (q), (r), (s) and (t), Sections 11, 13, 14(g), 16 through 31, and paragraph 12 (c) shall remain in full force and effect and shall survive the termination of this Agreement to the extent necessary to effect the express purposes of such paragraphs and Sections.

15. Publicity.

The parties hereto shall coordinate the preparation and issuance of any public announcement of this Agreement. Any such announcement shall comply with relevant Securities and Exchange Commission requirements and shall take into account any reasonable concern regarding the trade. The wording of such announcement shall be agreed upon by the parties before release.

16. Audits.

(a) Licensee shall keep accurate records of all Product sales and other relevant data concerning the Product for a period of two (2) years following the year in which such records were created and Licensee shall provide Licensor quarterly reports thereof forty-five (45) days after the end of the applicable calendar quarter. Such reports shall state the number of Units of Product manufactured by Licensee, its Affiliates or sublicensees and the number of Units of Product sold by Licensee, its Affiliates or sublicensees during the applicable quarter as well as the number of free samples of Product distributed and any Product returns made during such calendar quarter together with an accounting of any other applicable components of the amounts paid or to be paid hereunder with respect to such calendar quarter. Simultaneous with the delivery of such report, Licensee shall make, or cause to be made, any additional payment due with respect to the Purchase Price for Product sold during such calendar quarter. Once a year, upon reasonable notice, at times mutually agreed upon and during business hours, Licensor at Licensor's cost may have the accounts of Licensee, its Affiliates or sublicensees for the preceding two (2) calendar years relating to the Product reviewed by independent certified public accountants appointed by Licensor and reasonably approved by Licensee, solely in order to verify amounts due under this Agreement. Licensor and Licensee shall mutually determine a general strategy for such audit in advance of its conduct. Said accountant shall not disclose to Licensor any information except that which should properly be contained in a quarterly report required under this Agreement. Licensee shall promptly pay any underpayment evidenced by such audit, and Licensor shall promptly refund any overpayment evidenced by such audit. In the event such an audit evidences an underpayment of more than five percent (5%) with respect to the amounts actually paid, Licensee shall promptly pay such underpayment to Licensor with interest at the prime rate as set by Citibank, from the time when such underpayment accrued, and shall reimburse Licensor for the reasonable costs and expenses (including fees) of such audit.

(b) Licensor shall keep accurate records of its Direct Costs of manufacturing the Product for a period of two (2) years following the year in which such records were created. Once a year, upon reasonable notice, at times mutually agreed upon and during business hours, Licensee at Licensee's cost may have the accounts of Licensor for the preceding two (2) calendar years relating to the Direct Costs of manufacturing the Product reviewed by independent certified public accountants appointed by Licensee and reasonably approved by Licensor, solely in order to verify amounts due under this Agreement. Licensor and Licensee shall mutually determine a general strategy for such audit in advance of its conduct. Said accountant shall not disclose to Licensee any information except that relating to the Direct Costs of manufacturing the Product. Licensor shall promptly refund any overpayment evidenced by such audit, and Licensee shall promptly pay any underpayment evidenced by such audit. In the event such audit evidences an overpayment of more than five percent (5%) with respect to the amounts actually paid, Licensor shall promptly refund such overpayment to Licensee with interest at the prime rate as set by Citibank, from the time when such overpayments accrued, and shall reimburse Licensee for the reasonable costs and expenses (including fees) of such audit.

17. Notices.

All notices required hereunder shall be in writing and shall be deemed to be properly given if sent by air courier to the party to be notified at the address set forth on page 1 hereof, or at such other latest address as either party may hereafter designate in writing to the other; provided that a copy of each notice to be sent to Licensor hereunder shall also be sent by the same means to General Counsel, Columbia Laboratories, Inc., 000 Xxxxxxxxxx Xxxxxxx, Second Floor, Plaza Two, Livingston, Xxx Xxxxxx 00000, X.X.X.; and further provided that a copy of each notice sent to Licensee hereunder shall also be sent by the same means to Legal Department, Merck Serono S.A.-Geneva, 0 xxxxxx xxx Xxxxx, 0000 Xxxxxx, Xxxxxxxxxxx. The date of service of any notice so sent by air courier shall be the date of receipt.

18. Ownership Change; Assignment; Successors.

This Agreement shall be binding on and inure to the benefit of the successors and assigns of the parties, including any Affiliate, subsidiary, division or any entity controlled by either party. Except as provided herein, Licensee may not sublicense or assign this Agreement, in whole or in part, without the consent in writing of Licensor, and any purported assignment with such consent (which may be withheld without reason) shall be void; provided, that Licensee may upon notice to Licensor assign all or any portion of this Agreement to any of its Affiliates, but may not then sell such Affiliate without Licensor's prior written consent unless this Agreement is first assigned back from such Affiliate to Licensee. Licensor may not assign its rights under this Agreement, in whole or in part, without consent in writing of Licensee; and any purported assignment without such consent (which may be withheld without reason) shall be void; provided, that Licensor may upon notice to Licensee assign all or any portion of this Agreement to any of its Affiliates, but may not then sell such Affiliate without Licensee's prior written consent unless this Agreement is first assigned back from such Affiliate to Licensor.

If any person, individually or in concert with others, shall acquire directly or indirectly, through one or more intermediaries, the beneficial ownership of fifty percent or more of the equity or assets of Licensor or Licensee during the term of this Agreement, the party not being acquired may require from the new owners of the acquired party a written affirmation of its intent and capability to comply with all the terms of this Agreement. Under no circumstances shall such action by Licensor interfere with or compromise the continued supply of the Product to Licensee, provided, however, that should such interference or compromise occur, Licensee in such event shall have the option of terminating this Agreement.

Nothing in this Agreement, express or implied, is intended to confer on any person other than the parties hereto, or their respective permitted successors and assigns, any benefits, rights or remedies.

19. Tax.

All taxes levied on account of any payments accruing under this Agreement which constitute income to Licensor, shall be the obligation of Licensor, and if provision is made in law or regulation for withholding, such tax shall be deducted from any payment then due, paid to the proper taxing authority, and receipt for payment of the tax secured and promptly sent to Licensor.

20. Independent Contractors.

The relationship of the parties under this Agreement is that of independent contractors. Neither party shall be deemed to be the agent of the other and neither is authorized to take any action binding upon the other.

21. Entire Agreement; Modification.

This Agreement, including the Schedules hereto, contains the entire understanding between the parties hereto relating to the subject matter hereof, there being no terms and conditions other than those set forth herein, and it supersedes all prior agreements, written or oral, between the parties hereto with respect to the matters covered hereunder. This Agreement may not be modified, altered or otherwise changed other than by an instrument in writing, duly executed by each of the parties hereto. For avoidance of doubt, the terms of the Amended and Restated License and Supply Agreement dated as June 4, 2002 (as amended) shall remain in effect (as stated therein) until the Second A&R Agreement Date.

22. Severability.

If any provision of this Agreement should be or becomes fully or partly invalid or unenforceable for any reason whatsoever or should be adjudged to violate any applicable law, this Agreement is to be considered divisible as to such provision and such provision is deemed to be deleted from this Agreement, and the remainder of this Agreement shall be valid and binding as if such provision were not included herein; provided, however, that this Agreement is not rendered fundamentally different in its content or effect.

23. Effect of Headings.

The headings for the sections and paragraphs of this Agreement are to facilitate reference only, do not form a part of this Agreement, and shall not in any way affect the interpretation hereof.

24. Choice of Law.

This Agreement and performance hereof shall be construed and governed by the laws of the State of New York and of the United States. Any dispute, controversy, claim or difference arising between the parties out of, relating to, or in connection with this Agreement shall be submitted to the jurisdiction of the courts sitting in the State of New York.

25. No Waiver.

No delay or omission or failure to exercise any right or remedy provided for herein shall be deemed to be a waiver thereof or acquiescence in the event giving rise to such right or remedy.

26. Counterparts.

This Agreement may be executed in any number of counterparts and by the different parties hereto on separate counterparts, each of which, when so executed shall be deemed an original, but all such counterparts shall constitute but one and the same instrument.

27. Further Assurances.

Licensor and Licensee each agree to produce or execute such other documents or agreements as may be necessary or desirable for the execution and implementation of this Agreement and the consummation of the transactions contemplated hereby.

28. Schedules.

The terms and provisions of the Schedules attached to this Agreement are hereby incorporated herein as if fully set forth herein.

29. Bankruptcy.

All Trademark, Patent and Technology rights and licenses granted to the Product under or pursuant to this Agreement by Licensor to Licensee are, and shall otherwise be deemed to be, for purposes of Section 365(n) of the United States Bankruptcy Code, as amended from time to time (the "Bankruptcy Code"), licenses of rights to "intellectual property" as defined under Section 101 (35A) of the Bankruptcy Code, and any comparable law in the Territory. The parties hereto agree that so long as Licensee, as a licensee of such rights under this Agreement, makes all payments to Licensor required under this Agreement. Licensee shall retain and may fully exercise all of its rights and elections under the Bankruptcy Code. The parties further agree that, in the event that any proceeding shall be instituted by or against Licensor seeking to adjudicate it as bankrupt or insolvent, or seeking liquidation, winding up, reorganization, arrangement, adjustment, protection, relief or composition of it or its debts under any law relating to bankruptcy, insolvency or reorganization or relief of debtors, or seeking an entry of an order for relief or the appointment of a receiver, trustee or other similar official for it or any substantial part of its property or it shall take an action to authorize any of the foregoing actions, Licensee, as a licensee of such rights under this Agreement, shall retain and may fully exercise all of its rights and elections under the Bankruptcy Code. The parties further agree that, in the event of the commencement of a bankruptcy proceeding by or against Licensor under the Bankruptcy Code, Licensee shall be entitled to a complete duplicate of (or complete access to, as appropriate) any such intellectual property and all embodiment of such intellectual property, and the same, if not already in its possession, shall be promptly delivered to Licensee (i) upon any such commencement of a bankruptcy proceeding upon written request therefor by Licensee, unless Licensor elects to continue to perform all of its obligations under this Agreement, or (ii) if not delivered under (i) above, upon the rejection of this Agreement by or on behalf of Licensor, upon written request therefor by Licensee. In addition the parties agree that in such event the intellectual property delivered to Licensee shall include all Technology necessary or useful to give Licensee the capability of manufacturing the Product and such Technology shall be delivered to Licensee in such a way as to communicate it to Licensee promptly, effectively and economically.

30. Force Majeure.

No failure or omission by a party hereto in the performance of any obligation of this Agreement shall be deemed a breach of this Agreement nor shall it create any liability if the same shall arise from any cause or causes beyond the control of the party, including, but not limited to, the following, which, for the purposes of this Agreement, shall be regarded as beyond the control of the party in question: acts of God, acts or omissions of any government, any rules, regulations, or orders issued by any governmental authority or any officer, department, agency, or instrumentality thereof, fire, storm, flood, earthquake, accident, war, rebellion, insurrection, riot, invasion, strikes, lockouts; provided however, that the party so affected shall promptly advise the other party of the existence of such causes of nonperformance, shall use its best efforts to avoid or remove such causes of nonperformance and shall continue performance hereunder with the utmost dispatch whenever such causes are removed.

31. Performance by Affiliates.

The parties agree that certain of their rights and obligations under this Agreement may be carried out by one or more of their Affiliates; provided, however, that each party shall remain responsible for the acts and omission of its Affiliates. The parties further understand and agree that no such Affiliate is a party to this Agreement, and, except as contemplated by this Agreement, is not the agent of such party for purposes hereof, is not authorized to bind such party and cannot enter into amendments to this Agreement, which can only be made in accordance with the terms of Section 21 hereof.

IN WITNESS WHEREOF, the parties hereto have set their hands as of the day and year first above written,

Columbia Laboratories (Bermuda) Ltd.

By: /S/ Xxxxxx X. Xxxxx

(Title) President

Ares Trading S.A.

By: /S/ L. Foelisch 11/5/2010

(Title) VP Supply Chain

By: /S/ Xxxxxx Xxxx 12/5/2010

(Title) CFO

SCHEDULE A: CRINONE PATENTS

Case No.	Application No.	Patent No.	Publication No.	Title	Country	Current Status	Filing Date	Publication Date	Issue Date	Expiration Date
801505-00502	94928089.5	0719146		NOVEL METHOD OF PRGESTERONE DELIVERY AND AFFECT TEHREOF	EUROPEAN PATENT CONVENTION	ISSUED	9/13/1994		12/13/1998	9/13/2014
801505-00503	509291/95	3143474		NOVEL METHOD OF PROGESTERONE DELIVERY AND AFFECT THEREOF	JAPAN	ISSUED	9/13/1994		12/22/2000	9/13/2014
801505-00504	2,171,939	2,171,939		NOVEL METHOD OF PROGESTERONE DELIVERY AND AFFECT THEREOF	CANADA	ISSUED	9/13/1994		1/ 1/2002	9/13/2014
801505-00507	77261/94	689133		METHOD OF PROGESTERONE DELIVERY AND AFFECT THEREOF	AUSTRALIA	ISSUED	9/13/1994		7/ 9/1998	9/13/2014
801505-00508	273816	273816	1539	NOVEL METHOD OF PROGESTERONE DELIVERY AND AFFECT THEREOF	NEW ZEALAND	ISSUED	9/13/1994	9/28/2007	1/10/2008	9/13/2014
801505-00509	947089	199798		METHOD OF PROGESTERONE DELIVERY AND AFFECT THEREOF	MEXICO	ISSUED	9/14/1994		11/27/2000	9/14/2014
801505-00510	94928089.5	0719146		NOVEL METHOD OF PROGESTERONE DELIVERY AND AFFECT THEREOF	UNITED KINGDOM	ISSUED	9/13/1994		12/13/1998	9/13/2014
801505-00511	94928089.5	69415543.8		NOVEL METHOD OF PROGESTERONE DELIVERY AND AFFECT THEREOF	GERMANY	ISSUED	9/13/1994		12/13/1998	9/13/2014
801505-00512	94928089.5	0719146		NOVEL METHOD OF PROGESTERONE DELIVERY AND AFFECT THEREOF	FRANCE	ISSUED	9/13/1994		12/13/1998	9/13/2014
801505-00513	94928089.5	0719146		NOVEL METHOD OF PROGESTERONE DELIVERY AND AFFECT THEREOF	SWITZERLAND	ISSUED	9/13/1994		12/13/1998	9/13/2014
801505-00514	94928089.5	0719146		NOVEL METHOD OF PROGESTERONE DELIVERY AND AFFECT THEREOF	AUSTRIA	ISSUED	9/13/1994		12/13/1998	9/13/2014
801505-00515	94928089.5	0719146		NOVEL METHOD OF PROGESTERONE DELIVERY AND AFFECT THEREOF	SPAIN	ISSUED	9/13/1994		12/13/1998	9/13/2014
801505-00516	94928089.5	0719146		NOVEL METHOD OF PROGESTERONE DELIVERY AND AFFECT THEREOF	SWEDEN	ISSUED	9/13/1994		12/13/1998	9/13/2014
801505-00517	94928089.5	0719146		NOVEL METHOD OF PROGESTERONE DELIVERY AND AFFECT THEREOF	DENMARK	ISSUED	9/13/1994		12/13/1998	9/13/2014
801505-00518	94928089.5	0719146		NOVEL METHOD OF PROGESTERONE DELIVERY AND AFFECT THEREOF	NETHERLANDS	ISSUED	9/13/1994		12/13/1998	9/13/2014
801505-00519	94928089.5	0719146		NOVEL METHOD OF PROGESTERONE DELIVERY AND AFFECT THEREOF	BELGIUM	ISSUED	9/13/1994		12/13/1998	9/13/2014
801505-00520	94928089.5	0719146		NOVEL METHOF OF PROGESTERONE DELIVERY AND AFFECT THEREOF	ITALY	ISSUED	9/13/1994		12/13/1998	9/13/2014
801505-00521	94928089.5	0719146		NOVEL METHOD OF PROGESTERONE DELIVERY AND AFFECT THEREOF	IRELAND	ISSUED	9/13/1994		12/13/1998	9/13/2014
801505-00522	94928089.5	0719146		NOVEL METHOD OF PROGESTERONE DELIVERY AND AFFECT THEREOF	PORTUGAL	ISSUED	9/13/1994		12/13/1998	9/13/2014
801505-00523	94928089.5	0719146		NOVEL METHOD OF PROGESTERONE DELIVERY AND AFFECT THEREOF	MONACO	ISSUED	9/13/1994		12/23/1998	9/13/2014
801505-00524	94928089.5	3029314	0719146	NOVEL METHOD OF PROGESTERONE DELIVERY AND AFFECT THEREOF	GREECE	ISSUED	9/13/1994		12/13/1998	9/13/2014
801505-00525	961044	308585		NOVEL METHOD OF PROGESTERONE DELIVERY AND AFFECT THEREOF	NORWAY	ISSUED	9/13/1994		10/ 2/2000	9/13/2014
801505-00526	961221	115444		NOVEL METHOD OF PROGESTERONE DELIVERY AND AFFECT THEREOF	FINLAND	ISSUED	9/13/1994		5/13/2005	9/13/2014
801505-00527	94928089.5	0719146		NOVEL METHOD OF PROGESTERONE DELIVERY AND AFFECT THEREOF	LUXEMBOURG	ISSUED	9/13/1994		12/13/1998	9/13/2014
801505-00531	329462	AR 256069 V1		METHOD OF PROGESTERONE DELIVERY AND AFFECT THEREOF	ARGENTINA	ISSUED	9/14/1994		12/22/2004	12/22/2019
801505-00532	1319-94	39.553		NOVEL METHOD OF PROGESTERONE DELIVERY AND AFFECT THEREOF	CHILE	ISSUED	9/ 9/1994		6/15/1998	6/15/2013
801505-00534	250745	1208		NOVEL METHOD OF PROGESTERONE DELIVERY AND AFFECT THEREOF	PERU	ISSUED	9/15/1994		4/29/1999	9/15/2014
801505-00535	1817-94	1817-94		NOVEL METHOD OF PROGESTERONE DELIVERY AND AFFECT THEREOF	VENEZUELA	ISSUED	11/23/1994		10/14/1999	11/23/2014
801505-00539	23,329	23,329		NOVEL METHOD OF PROGESTERONE DELIVERY AND AFFECT THEREOF	MOROCCO	ISSUED	9/14/1994		4/17/1995	9/14/2014
801505-00540	94/7073	94/7073		NOVEL METHOD OF PROGESTERONE DELIVERY AND AFFECT THEREOF	SOUTH AFRICA	ISSUED	9/14/1994		7/26/1995	9/14/2014
801505-00541	110972	110972		PHARMACEUTICAL PREPARATIONS FOR INTRAVAGINAL ADMINISTRATION OF PROGESTERONE	ISRAEL	ISSUED	9/14/1994		6/11/1998	9/14/2014
801505-00551	PI9402436	MY-111484-A		NOVEL METHOD OF PROGESTERONE DELIVERY AND AFFECT THEREOF	MALAYSIA	ISSUED	9/14/1994		6/30/2000	6/30/2015
801505-00560	96108813	2148393		METHOD OF PROGESTERONE DELIVERY AND AFFECT THEREOF	FEDERATION OF RUSSIA	ISSUED	9/13/1994		3/10/2000	9/13/2014
801505-00561	P9600669	221583		NOVEL METHOD OF PROGESTERONE DELIVERY AND AFFECT THEREOF	HUNGARY	ISSUED	9/13/1994		2/ 3/2003	9/13/2014
801505-00564	1202/01-96	1956		METHOD OF PROGESTERONE DELIVERY AND AFFECT THEREOF	GEORGIA	ISSUED	9/13/1994		12/ 5/1999	9/13/2014
801505-00565	00-000	0000		METHOD OF PROGESTERONE DELIVERY AND AFFECT THEREOF	LITHUANIA	ISSUED	9/13/1994		12/ 4/1996	9/13/2014
801505-00566	96030993	37244		METHOD OF PROGESTERONE DELIVERY AND AFFECT THEREOF	UKRAINE	ISSUED	9/13/1994		5/15/2001	9/13/2014
801505-00568	P-96-113	11527		METHOD OF PROGESTERONE DELIVERY AND AFFECT THEREOF	LATVIA	ISSUED	9/13/1994		2/20/1997	9/13/2014

SCHEDULE B: TRADEMARKS

CRINONE

Country	Serial Number	Filing Date	Status

Antigua	3739	07/15/94	Reg. No. 3739 Reg. Date. 07/15/94
Argentina	2.507.805	04/16/04	Reg. No. 1,535,140 Reg. Date: 08/31/94
Aruba	96070622	06/03/94	Reg. No. 16860 Reg. Date: 07/06/94
Australia	622,906	02/17/94	Reg. No. A622,906 Reg. Date: 10/05/95
Austria	AM 706/94	02/16/94	Reg. No. 152,207 Reg. Date: 04/20/94
Bahamas	16,603	07/18/94	Reg. No. 16,603 Reg. Date: 07/15/94
Barbados	81/11219	09/01/94	Reg. No. 81/11219 Reg. Date 12/29/00
Bermuda	99127654	12/02/94	Reg. No. 26575 Reg. Date: 12/02/94
Bolivia	97003902	09/16/97	Reg. No. 72444 Reg. Date: 04/08/99
Brazil	817,711,643	03/01/94	Reg. No. 817711643 Reg. Date: 09/17/96
Bulgaria	36027	09/09/96	Reg. No. 30906 Reg. Date: 06/19/97
Canada	748,373	03/01/94	Reg. No. TMA 519903 Reg. Date : 11/25/99
Chile	266,724	02/18/94	Reg. No. 435,742 Reg. Date: 01/02/95
China	960100880	09/04/96	Reg. No. 1118238 Reg. Date: 10/14/97
China (Chinese Characters)	2001016425	02/06/01	Reg. No. 1732465 Reg. Dt. 03/20/12
Columbia	94009937	03/11/94	Reg. No. 163,531 Reg. Date: 06/30/94
Costa Rica	4,426/403	03/17/94	Reg. No. 89,706 Reg. Date: 01/03/95
Xxxxx Xxxxxxxx	000000	09/13/96	Reg. No. 208 376 Reg. Date: 03/25/98
Denmark	01294/1994	02/16/94	Reg. No. 3,349/1994 Reg. Date: 05/20/94
Dominica	Not available	01/11/95	Reg. No. 2/95 Reg. Date: 10/26/95
Dominican Republic	Not available	Not available	Reg. No. 74,643 Reg. Date: 10/15/94
Ecuador	45,168	02/17/94	Reg. No. 2513-95 Reg. Date: 07/14/95
El Salvador	E-4343/96	09/27/96	Reg. No. 14 book 65 Reg. Date : 12/09/97

SCHEDULE B: TRADEMARKS

CRINONE

Country	Serial Number	Filing Date	Status
Finland	868/94	02/17/94	Reg. No. 135,416 Reg. Date: 12/05/94
France	94/507,153	02/18/94	Reg. No. 94/507,153 Reg. Date: 02/18/94
Gaza	2649	02/21/95	Reg. No. 2649 Reg. Date: 11/10/95
Germany	C 46 417/5 SWz	02/15/94	Reg. No. 2105212 Reg. Date: 11/19/98
Greece	118.091	03/04/94	Reg. No. 118091 Reg. Date: 09/17/96
Grenada	Not available	Not available	Reg. No. 17 of 1995 Reg. Date: 03/07/95
Guatemala	5530/94	08/18/94	Reg. No. 79985/314/171 Reg. Date: 08/05/96
Honduras	3,319/94	04/29/94	Reg. No. 3,319/94 Reg. Date: 12/11/95
Hong Kong	94/01,823	02/18/94	Reg. No. 6779/1995 Reg. Date: 08/10/95
Hungary	M9602956	09/09/96	Reg. No. 149,548 Reg. Date: 03/12/98
Iceland	986/1996	08/16/96	Reg. No. 1305/1998 Reg. Date: 12/02/98
India	686888	11/15/95	Reg. No. 686888 Reg. Date : 11/15/95
Indonesia	Not available	02/25/94	Reg. No. 334.556 Reg. Date: 02/25/94
Ireland	94/1,054	02/21/94	Reg. No. 161 455 Reg. Date: 11/16/95
Israel	91,275	02/16/94	Reg. No. 91,275 Reg. Date: 03/11/95
Italy	MI 94C-001,468	02/18/94	Reg. No. 693083 Reg. Date: 11/26/96
Jamaica	5/6002	07/22/94	Reg. No. 27,566 Reg. Date: 07/22/94
Japan	16,695/94	02/17/94	Reg. No. 4.007.106 Reg. Date: 06/06/971
Korea	04-6072	02/17/94	Reg. No. 327,934 Reg. Date: 11/28/95
Malaysia	94/01,482	02/28/94	Reg. No. 04/101,482 Reg. Date: 01/06/96
Mexico	194,789	03/28/94	Reg. No. 461,390 Reg. Date: 05/23/94

1 Registered in the name of Ishihara Sangyo Kaisha, Ltd. pursuant to license agreement.

SCHEDULE B: TRADEMARKS

CRINONE

Country	Serial Number	Filing Date	Status
New Zealand	235,877	04/12/94	Reg. No. 235877 Reg. Date: 04/12/94
Nicaragua	94-00692	03/15/94	Reg. No. 27140 Reg. Date: 11/08/94
Norway	94.1168	02/24/94	Reg. No. 167,793 Reg. Date: 05/04/95
Pakistan	133195	01/17/96	Reg. No. 133195 Reg. Date: 12/04/95
Panama	75,910	06/09/95	Reg. No. 075910 Reg. Date: 03/09/98
Peru	237,422	02/25/94	Reg. No. 7560 Reg. Date: 05/24/94
Philippines	93,975	07/01/94	Reg. No. 0-0000-00000 Reg. Date : 04/12/00
Poland	Z-164,217	09/16/96	Reg. No. 112438 Reg. Date : 01/24/00
Portugal	298,172	02/17/94	Reg. No. 298,177 Reg. Date: 05/18/95
Romania	40973	09/19/96	Reg. No. 30355 Reg Date : 09/19/96
St. Kitts & Nevis	4201	07/12/94	Reg. No. 4201 Reg. Date: 07/12/94
St. Lucia	Not available	11/09/94	Reg. No. 251 of 1994 Reg. Date: 02/21/95
St. Xxxxxxx	Not available	Not available	Reg. No. 5 of 1995 Reg. Date: 01/18/95
Saudi Arabia	26,156	02/26/94	Reg. No. 342/76 Reg. Date: 02/26/94
Singapore	1,504/94	02/22/94	Reg. No. 1504/94 Reg. Date: 02/22/94
Xxxxxx Xxxxxxxx	0000-00	09/17/96	Reg. No. 186997 Reg. Date : 09/20/99
South Africa	941,526	02/15/94	Reg. No. 94/1526 Reg. Date: 05/08/96
South Korea	94-6072	02/17/94	Reg. No. 327,934 Reg. Date: 11/28/95
Spain	2466756	04/02/02	Reg. No. 24667565 Reg. Date: 02/05/03
Sweden	C-94-01662	02/15/94	Reg. No. 263,029 Reg. Date: 12/23/94
Switzerland	1078/1994.0	02/17/94	Reg. No. 420,589 Reg. Date: 02/17/94
Taiwan	(83)8061	02/24/94	Reg. No. 665,209 Reg. Date: 02/24/94
Taiwan (Characters)	(00)000000	00/02/00	Reg. No. 975334 Reg. Date: 12/16/01
Thailand	261,887	03/15/94	Reg. No. 28243 Reg. Date : 04/24/95
Trinidad	22,865	07/08/94	Reg. No. 22866 Reg. Date : 07/05/95
Turkey	2007/46781	08/31/07
United Kingdom	1,562,409	02/15/94	Reg. No. 1,562,409 Reg. Date: 02/15/94
Uruguay	269,001	03/18/94	Reg. No. 269,001 Reg. Date: 03/21/96
Venezuela	2,201	02/22/94	Reg. No. P-183-410 Reg. Date : 01/05/96
Vietnam	NH 1790/96	11/04/96	Reg. No. 26281 Reg. Date : 01/24/98

SCHEDULE B: TRADEMARKS

PERLENCE

Country	Serial Number	Filing Date	Status
Benelux	905081	11/19/97
Bulgaria	38213	04/25/97
Xxxxx Xxxxxxxx	000000	05/20/97
Denmark	05748/1997	12/21/97	Reg. No. UR 05.416 1997 Reg. Date: 12/19/97
Finland	T 199704540	11/20/97	Reg. No. 211692 Reg. Date: 10/30/98
France CORLUTRONE	96/657727	12/31/96	Reg. No. 96/657727 Reg. Date: 12/31/96 Reg. No. 96 636870 Reg. Date: 07/31/96
Hungary	M97 01450	04/24/97
Norway	19979915	11/26/97	Reg. No. 192405 Reg. Date: 08/27/98
Poland	Z 173351	05/12/97
Romania		05/20/97
Xxxxxx Xxxxxxxx	XXX 0000-00	00/00/00
Xxxxxx	97-10435	11/20/97

SCHEDULE C. CLINICAL TRIALS

Protocol 1620-302	PREGNANT Study, a Phase III clinical trial to reduce the risk of preterm birth in women with a short cervix as measured by transvaginal ultrasound in mid-pregnancy
Protocol 1620-301	Multiple Dose Pharmacokinetics Study, an evaluation of pre-dose and post-dose plasma levels of Prochieve 8% during the 28th week of pregnancy after several weeks of dosing in 19 pregnant patients
Protocol 1620-300	A Phase III clinical trial to reduce the risk of preterm birth in 637 women with a history of preterm birth in the immediately preceding pregnancy

SCHEDULE D. ASSIGNMENT PROCESS OF TRADEMARKS TO LICENSEE

1. Licensee’s Trademarks Department shall provide the Licensor with the list of Licensee’s agents that handle trademark matters in the countries covered by the Trademarks under schedule B. The point of contact at Licensor’s Trademarks Department is Xx Xxxxxxx XxXxxxx.

2. Within 30 days of receipt by Licensee ot the agents list, Licensor will instruct its agents that handle the Trademarks, to contact Licensee’s agents to arrange the assignment of all rights and interest in the Trademarks, and related goodwill, to the Licensee and to transfer the administration of the Trademarks to Licensee’s agents.

3. The assignment and transfer process will be centralized and handled by the Licensor. Licensee’s Trademarks Department shall provide all necessary support in this process including the signature and legalization of assignment documents. The points of contact at Licensee’s Trademarks Department are Xxx Xxxxx Xxxxxxx and Xx Xxxx Xxxxxx.

4. The assignment process outlined in this Schedule D should be completed within one year from the receipt of the list in point 1

SCHEDULE E. LICENSOR DOMAIN NAME

A Licensor Domain Name contains one of the following subdomains, together with any top level domain, including without limitation “.com”, “.net”, “.us”, ”.biz”, “.info”:

crinoneus

crinone-us

crinone_us

crinoneusa

crinone-usa

crinone_usa

SCHEDULE F. : LICENSEE DOMAIN NAMES

CRINONE REGISTERED DOMAIN NAMES IN THE NAME OF ARES TRADING S.A.

Domain	Owner	Domain	Owner
xxxxxxx.xx	Ares Trading SA	xxxxxxx.xx	Ares Trading SA
xxxxxxx.xxx	Ares Trading SA	xxxxxxx.xx	Ares Trading SA
xxxxxxx.xxx	Ares Trading SA	xxxxxxx.xx	Ares Trading SA
xxxxxxx.xx	Ares Trading SA	xxxxxxx.xx	Ares Trading SA
xxxxxxx.xxx	Ares Trading SA	xxxxxxx.xx	Ares Trading SA
xxxxxxx.xx	Ares Trading SA	xxxxxxx.xx	Ares Trading SA
xxxxxxx.xx	Ares Trading SA	xxxxxxx.xx	Ares Trading SA
xxxxxxx.xxxx	Ares Trading SA	xxxxxxx.xx	Ares Trading SA
xxxxxxx.xx	Ares Trading SA	xxxxxxx.xxx.xx	Ares Trading SA
xxxxxxx.xx.xx	Ares Trading SA	xxxxxxx.xx	Ares Trading SA
xxxxxxx.xx.xx	Ares Trading SA	xxxxxxx.xxx.xx	Ares Trading SA
xxxxxxx.xx	Ares Trading SA	xxxxxxx.xx	Ares Trading SA
xxxxxxx.xx	Ares Trading SA	xxxxxxx.xx	Ares Trading SA
xxxxxxx.xx	Ares Trading SA	xxxxxxx.xx	Ares Trading SA
xxxxxxx.xxx	Ares Trading SA	xxxxxxx.xx	Ares Trading SA
xxxxxxx.xx	Ares Trading SA	xxxxxxx.xxx.xx	Ares Trading SA
xxxxxxx.xx	Ares Trading SA	xxxxxxx.xxx.xx	Ares Trading SA
xxxxxxx.xxxx	Ares Trading SA	xxxxxxx.xxx.xx	Ares Trading SA
xxxxxxx.xxx.xx	Ares Trading SA	xxxxxxx.xxx.xx	Ares Trading SA
xxxxxxx.xxx.xx	Ares Trading SA	xxxxxxx.xxx	Ares Trading SA
xxxxxxx.xxx.xx	Ares Trading SA	xxxxxxx.xx.xx	Ares Trading SA

SCHEDULE G: LICENSEE TRADEMARKS

CRINONE REGISTERED TRADEMARKS IN THE NAME OF ARES TRADING S.A.

	Trademark	Country	Appl No	Appl Date	Reg Xx	Xxx Xxxx
XXXXXXX		Xxxxxx Xxxx Xxxxxxxx	00000	28.05.2006	84167	11.09.2007
XXXXXXX		Xxxxxxxxxx	00000	04.05.2006
XXXXXXX		Xxxxxxx	00000	09.05.2006	47946	09.05.2006
XXXXXXX		Xxxxxxxxxxx	00000/0000	08.05.2006	547508	29.06.2006
XXXXXXX		Xxxxx	000000	14.09.2008
CRINONE		European Community	4.033.049	17.09.2004	4.033.049	03.01.2006
CRINONE		Iraq	To be deleted
CRINONE		Jordan
XXXXXXX		Xxxxxx	000/X	00.00.0000
XXXXXXX		Xxxxxx	76965	06.05.2006	67592	06.05.2006
XXXXXXX		Xxxxxxx	000000	16.06.2006	107126	16.06.2006
XXXXXXX		Xxx Xxxxx	000000	08.06.2006
CRINONE		Libya	11179	23.05.2007
CRINONE		Myanmar	4/5709/2006	25.08.2006	4/5709/2006	29.08.2006
CRINONE		Mauritius	MU/M/06/04521	15.05.2006	03193/2007	24.04.2007
XXXXXXX		Xxxxx	00000	07.05.2006	39629	24.01.2008
CRINONE		Int. Agreement & Protocol	890.724	29.06.2006	890.724	29.06.2006
Crinone in Cyrillic		Russia	2004723529	14.10.2004	296595	10.10.2005
crinone in hebrew		Israel	175730	21.10.2004	175730	05.04.2006
crinone in hebrew		Israel	175729	21.10.2004	175729	05.04.2006
xxxxxxx xx xxxxxx		Xxxxxx Xxxx Xxxxxxxx	00000	13.03.2006	89762	23.06.2008
xxxxxxx xx xxxxxx		Xxxxxxx	00000	13.03.2006	47179	13.03.2006
xxxxxxx xx xxxxxx		Xxxxxx	000000	14.03.2006	188536	11.11.2007
crinone in arabic		Iraq	49181	05.04.2006
crinone in arabic		Iran	85020487	26.04.2006	136065	23.10.2006
crinone in arabic		Jordan	85966	15.03.2006	85996	29.03.2007
crinone in arabic		Kuwait	75686	11.03.2006	67554	11.03.2006
xxxxxxx xx xxxxxx		Xxxxxxx	000000	24.03.2006	105884	24.03.2006
xxxxxxx xx xxxxxx		Xxxx	00000	14.03.2006	39350	22.05.2007
xxxxxxx xx xxxxxx		Xxxxx	00000	12.03.2006	38924	28.11.2007
crinone in arabic		Xxxxx Xxxxxx	000000	11.03.2006	898/26	21.02.2007
crinone in arabic		Sudan	35072	09.03.2006

Document Metadata

Table of Contents

SECOND AMENDED AND RESTATED LICENSE AND SUPPLY AGREEMENT

Document Metadata